Ranbaxy Set To Sell 50% Of Pfizer Lipitor Versions By May, Insiders Say
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories controlled nearly half the U.S. market during the six months it had exclusive rights to sell a generic version of Pfizer’s cholesterol drug Lipitor (atorvastatin).